Richard Press

Dr. Richard Press

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Cancer Cell
Verified
Journal Article
Closed access
MZMatthew S. Zabriskie
Matthew S. Zabriskie
CEChristopher A. Eide
Christopher A. Eide
STSrinivas K. Tantravahi
Srinivas K. Tantravahi
NVNadeem A. Vellore
Nadeem A. Vellore
JEJohanna Estrada
Johanna Estrada
TOThomas O’hare
Thomas O’hare

15 October 2008 in Blood
Verified
Journal Article
Closed access
PDF file
SBSusan Branford
Susan Branford
LFLinda Fletcher
Linda Fletcher
NCNicholas C. P. Cross
Nicholas C. P. Cross
MMMartin C. Müller
Martin C. Müller
AHAndreas Hochhaus
Andreas Hochhaus
THTimothy Peter Hughes
Timothy Peter Hughes
An international basis for comparison of BCR-ABL mRNA levels is required for the common interpretation of data derived from individual laboratories. This will aid clinical decisions for individual patients with chronic myeloid leukemia (CML) and assist interpretation of results from clinical studies. We aligned BCR-ABL values generated by 38 laboratories to an international scale (IS) where a major molecular response (MMR) is 0.1% or less. Alignment was achieved by application of laboratory-specific conversion factors calculated by comparisons performed with patient samples against a reference method. A validation procedure was completed for 19 methods. We determined performance characteristics (bias and precision) for consistent interpretation of MMR after IS conversion. When methods achieved an average BCR-ABL difference of plus or minus 1.2-fold from the reference method and 95% limits of agreement within plus or minus 5-fold, the MMR concordance was 91%. These criteria were met by 58% of methods. When not met, the MMR concordance was 74% or less. However, irrespective of precision, when the bias was plus or minus 1.2-fold as achieved by 89% of methods, there was good agreement between the overall MMR rates. This indicates that the IS can deliver accurate comparison of molecular response rates between clinical trials when measured by different laboratories.

8 December 2011 in Blood
Verified
Journal Article
Open access
PDF file
AFAngela Fleischman
Angela Fleischman
KAKarl J. Aichberger
Karl J. Aichberger
SLSamuel B. Luty
Samuel B. Luty
TBThomas G. Bumm
Thomas G. Bumm
CPCurtis L. Petersen
Curtis L. Petersen
MDMichael W. Deininger
Michael W. Deininger
Proinflammatory cytokines such as TNFα are elevated in patients with myeloproliferative neoplasms (MPN), but their contribution to disease pathogenesis is unknown. Here we reveal a central role for TNFα in promoting clonal dominance of JAK2V617F expressing cells in MPN. We show that JAK2V617F kinase regulates TNFα expression in cell lines and primary MPN cells and TNFα expression is correlated with JAK2V617F allele burden. In clonogenic assays, normal controls show reduced colony formation in the presence of TNFα while colony formation by JAK2V617F-positive progenitor cells is resistant or stimulated by exposure to TNFα. Ectopic JAK2V617F expression confers TNFα resistance to normal murine progenitor cells and overcomes inherent TNFα hypersensitivity of Fanconi anemia complementation group C deficient progenitors. Lastly, absence of TNFα limits clonal expansion and attenuates disease in a murine model of JAK2V617F-positive MPN. Altogether our data are consistent with a model where JAK2V617F promotes clonal selection by conferring TNFα resistance to a preneoplastic TNFα sensitive cell, while simultaneously generating a TNFα-rich environment. Mutations that confer resistance to environmental stem cell stressors are a recognized mechanism of clonal selection and leukemogenesis in bone marrow failure syndromes and our data suggest that this mechanism is also critical to clonal selection in MPN.

14 August 2024 in Nature
Verified
Journal Article
Closed access
PDF file
PPPetri Pölönen
Petri Pölönen
DGDanika Di Giacomo
Danika Di Giacomo
Anna Eames SeffernickAnna Eames Seffernick
Anna Eames Seffernick
AEAbdelrahman Elsayed
Abdelrahman Elsayed
SKShunsuke Kimura
Shunsuke Kimura
DTDavid Trent Teachey
David Trent Teachey

25 November 2010 in Blood
Verified
Journal Article
Closed access
PDF file
HWHelen E. White
Helen E. White
PMPaul Matejtschuk
Paul Matejtschuk
PRPeter Rigsby
Peter Rigsby
JGJean Gabert
Jean Gabert
FLFeng Lin
Feng Lin
NCNicholas C. P. Cross
Nicholas C. P. Cross
Serial quantitation of BCR-ABL mRNA levels is an important indicator of therapeutic response for patients with chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia, but there is substantial variation in the real-time quantitative polymerase chain reaction methodologies used by different testing laboratories. To help improve the comparability of results between centers we sought to develop accredited reference reagents that are directly linked to the BCR-ABL international scale. After assessment of candidate cell lines, a reference material panel comprising 4 different dilution levels of freeze-dried preparations of K562 cells diluted in HL60 cells was prepared. After performance evaluation, the materials were assigned fixed percent BCR-ABL/control gene values according to the International Scale. A recommendation that the 4 materials be established as the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL translocation by real-time quantitative polymerase chain reaction was approved by the Expert Committee on Biological Standardization of the World Health Organization in November 2009. We consider that the development of these reagents is a significant milestone in the standardization of this clinically important test, but because they are a limited resource we suggest that their availability is restricted to manufacturers of secondary reference materials.

15 December 1996 in Circulation
Verified
Journal Article
Closed access
TDThomas G. Deloughery
Thomas G. Deloughery
AEAdam Evans
Adam Evans
ASAbbas Sadeghi
Abbas Sadeghi
JMJeffrey McWilliams
Jeffrey McWilliams
WHW. David Henner
W. David Henner
RPRichard Press
Richard Press
Background Increased homocysteine levels are a risk factor for atherosclerosis and its sequelae. A common genetic mutation in methylenetetrahydrofolate reductase (MTHFR), an enzyme required for efficient homocysteine metabolism, creates a thermolabile enzyme with reduced activity. We determined the prevalence of this mutation in many subjects with and without vascular disease and related it to homocysteine and folate levels. Methods and Results DNA from 247 older subjects with vascular disease and 594 healthy subjects without vascular disease (in three different control groups) was screened for the MTHFR 677 C-to-T mutation. Within each group, 9% to 17% of the subjects were homozygous for this mutation, and the mutant allele frequency was 31% to 39%. The genotype distributions, homozygote frequencies, and allele frequencies did not differ significantly between the study groups. In the vascular disease subjects, despite significantly lower folate levels in MTHFR homozygotes, there was no significant difference in homocysteine levels among the MTHFR genotype groups. The negative slope of the regression line relating homocysteine and folate was significantly steeper for those with a homozygous MTHFR mutation compared with those without this mutation. Conclusions Although the thermolabile MTHFR mutation is very common, it does not appear to be a significant genetic risk factor for typical late-onset vascular disease. Because MTHFR homozygotes have increased homocysteine with low folate levels, this mutation may contribute to early-onset or familial vascular disease. The genotype dependence of the folate-homocysteine correlation further suggests that homozygotes for this mutation may have both an exaggerated hyperhomocysteinemic response to folic acid depletion and a better response to folic acid therapy.